TriSalus Life Sciences (TLSI) Net Margin (2022 - 2026)

TriSalus Life Sciences' Net Margin history runs 5 years deep, the most recent figure standing at 17.29% for Q1 2026.

• On a quarterly basis, Net Margin rose 13824.0% year-over-year to 17.29% in Q1 2026; TTM through Mar 2026 was 130.32%, a 3600.0% decrease from a year earlier, with the FY2025 full-year figure at 154.35%, down 4143.0% from the prior year.
• Net Margin grew to 17.29% in Q1 2026 per TLSI's latest filing, from 73.86% in the prior quarter.
• Across five years, Net Margin topped out at 17.29% in Q1 2026 and bottomed at 786.45% in Q4 2022.
• The 5-year median for Net Margin is 131.84% (2024), against an average of 226.58%.
• Across the five-year window, Net Margin jumped 50510 bps in 2024 and sank 31329 bps in 2025, its largest moves.
• Year by year, Net Margin stood at 786.45% in 2022, then advanced by 19 bps to 636.93% in 2023, then soared by 79 bps to 131.84% in 2024, then surged by 44 bps to 73.86% in 2025, then jumped by 123 bps to 17.29% in 2026.
• Per Business Quant, the three latest TLSI Net Margin figures stand at 17.29% (Q1 2026), 73.86% (Q4 2025), and 356.86% (Q3 2025).